Plasma Protein Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Plasma Protein Therapeutics Market is projected to expand from USD 33.26 Billion in 2025 to USD 49.27 Billion by 2031, reflecting a CAGR of 6.77%. These biologic medicines, obtained through the fractionation of human blood plasma, are essential for managing rare and chronic life-threatening diseases such as primary immunodeficiencies and hemophilia. Market expansion is primarily fueled by the rising diagnosis of neurological and immunological disorders that necessitate lifelong replacement therapies, coupled with an aging global population requiring ongoing medical care. Additionally, progress in diagnostic technologies continues to widen the identified patient base, demanding a steady increase in production independent of transient consumption patterns.

A major obstacle hindering wider market growth is the difficulty of sustaining a robust supply chain, which currently depends heavily on a few specific geographic areas for raw material collection. This concentration exposes the industry to risks from regulatory shifts or logistical interruptions that could jeopardize global supply availability. According to the Plasma Protein Therapeutics Association, North American donors contributed over 63% of the world's plasma supply for manufacturing in 2025. As a result, attaining regional self-sufficiency remains a significant barrier to stabilizing the market and satisfying increasing international requirements.

Market Drivers

The rising global demand for immunoglobulin therapies serves as a primary growth engine, spurred by the increasing use of immunoglobulins (IG) for treating primary and secondary immunodeficiencies. With improved diagnostic rates and clinical applications expanding to neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), patient dependence on these lifelong treatments has grown significantly. Manufacturers are observing strong adoption of both intravenous and subcutaneous formulations, requiring increased output to avoid shortages for the growing patient population. Highlighting this trend, CSL Limited reported in its 'Half Year Results 2025' from February 2025 that its immunoglobulin portfolio achieved sales of $3.17 billion, marking a 15% rise from the prior period, which underscores the vital role of IG products in the financial growth of key market players.

Simultaneously, the expansion of global plasma collection infrastructure is essential as the industry scales to secure the raw materials needed for fractionation. Companies are making substantial investments to broaden their donor center networks and refine supply chain logistics, aiming to reduce regional reliance and boost collection yields. This structural development is crucial for stabilizing the plasma volume required to manufacture therapies like coagulation factors and albumin. For instance, Forbes noted in a February 2025 article, 'Inside Takeda's Plasma-Derived Therapy Ecosystem', that Takeda now collects over 15 million liters of plasma annually to meet production demands. Furthermore, the market's overall financial resilience is evident, with Grifols reporting total annual revenues of €7.2 billion in its 'Fourth Quarter and Full Year 2024 Results' released in February 2025.

Market Challenges

The primary obstacle constraining the Global Plasma Protein Therapeutics Market is the instability of its supply chain, which is defined by an excessive dependence on a select few geographic regions for source plasma collection. This concentrated reliance establishes a risky bottleneck where global product availability is disproportionately linked to the operational continuity of a single region. Consequently, any local policy changes or logistical disruptions in this primary source area could precipitate worldwide shortages, thereby hindering manufacturers from scaling up production to reliably meet the growing demand for life-saving treatments.

This severe infrastructure imbalance significantly impedes the industry's efforts to diversify its raw material origins. Data from the Plasma Protein Therapeutics Association highlights this disparity; in 2024, the collection landscape was so uneven that the state of Texas alone maintained 178 plasma centers, exceeding the 177 centers found throughout the entire continent of Europe. Such a stark contrast emphasizes the market's susceptibility to regional limitations. Until collection capacity becomes less geographically restricted, the industry will struggle to secure the resilient supply volumes required to sustain global market expansion.

Market Trends

The shift toward subcutaneous immunoglobulin administration is fundamentally altering the market by moving treatment from clinical environments to flexible home-based care settings. This transition is driven by the creation of high-concentration formulations that enable patients with primary immunodeficiencies to self-administer their treatments, greatly enhancing quality of life while decreasing the logistical strain on hospitals. The growing preference for these convenient dosing options is fueling specific growth within the immunoglobulin sector, surpassing traditional intravenous methods as manufacturers launch user-friendly delivery systems. According to CSL Limited’s 'Half Year Results 2025' from February 2025, sales of the subcutaneous product HIZENTRA rose by 16% over the previous period, spurred specifically by the robust adoption of pre-filled syringe options.

At the same time, the adoption of advanced chromatographic fractionation techniques is emerging as a critical trend as manufacturers aim to maximize protein recovery from every liter of collected plasma. Confronted with elevated raw material costs, companies are rapidly integrating automated purification processes to boost the yield of valuable proteins, effectively decoupling production volumes from linear collection growth. This strategic emphasis on operational efficiency allows producers to reduce the cost per gram of protein and enhance profitability despite donor market volatility. As reported in Grifols’ 'Fourth Quarter and Full Year 2024 Results' in February 2025, the company attained an Adjusted EBITDA margin of 26.6% in the fourth quarter, a result largely credited to ongoing yield improvements and the successful implementation of its operational optimization strategy.

Key Players Profiled in the Plasma Protein Therapeutics Market

• Grifols, S.A.
• CSL Behring AG
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxalta Incorporated
• Kedrion S.p.A.
• LFB S.A.
• Bio Products Laboratory Ltd.
• Shanghai RAAS Blood Products Co., Ltd.
• Haema AG

Report Scope

In this report, the Global Plasma Protein Therapeutics Market has been segmented into the following categories:

Plasma Protein Therapeutics Market, by Product:

• Immunoglobulin
• Albumin
• Plasma Derived Clotting Factor
• Fibrinogen
• Others

Plasma Protein Therapeutics Market, by Application:

• Hemophilia
• Primary Immunodeficiency Disorder (PID)
• Idiopathic Thrombocytopenic Purpura (ITP)
• Others

Plasma Protein Therapeutics Market, by End User:

• Hospitals
• Research Laboratories and Institutions
• Stand-Alone Blood Banks
• Others

Plasma Protein Therapeutics Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasma Protein Therapeutics Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.